Pharming Group (PHAR) Competitors $13.60 -1.21 (-8.17%) Closing price 03:51 PM EasternExtended Trading$13.52 -0.07 (-0.55%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. SRRK, VKTX, MIRM, LNTH, ADMA, ACAD, ZLAB, QURE, CGON, and AAPGShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), uniQure (QURE), CG Oncology (CGON), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Scholar Rock Viking Therapeutics Mirum Pharmaceuticals Lantheus ADMA Biologics ACADIA Pharmaceuticals Zai Lab uniQure CG Oncology Ascentage Pharma Group International Scholar Rock (NASDAQ:SRRK) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings. Do institutionals & insiders have more ownership in SRRK or PHAR? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, SRRK or PHAR? Scholar Rock has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Does the media prefer SRRK or PHAR? In the previous week, Scholar Rock had 4 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.71 beat Scholar Rock's score of -0.01 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SRRK or PHAR? Scholar Rock presently has a consensus target price of $48.50, suggesting a potential upside of 63.41%. Pharming Group has a consensus target price of $30.00, suggesting a potential upside of 120.59%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07Pharming Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Is SRRK or PHAR more profitable? Scholar Rock has a net margin of 0.00% compared to Pharming Group's net margin of -2.19%. Pharming Group's return on equity of -3.31% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -127.11% -90.09% Pharming Group -2.19%-3.31%-1.78% Which has stronger valuation and earnings, SRRK or PHAR? Pharming Group has higher revenue and earnings than Scholar Rock. Pharming Group is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M85.96-$246.29M-$2.91-10.20Pharming Group$339.84M2.74-$11.84M-$0.13-104.62 SummaryScholar Rock beats Pharming Group on 10 of the 17 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$931.80M$3.42B$6.14B$10.76BDividend YieldN/A2.26%5.71%4.83%P/E Ratio-104.6223.3029.8028.54Price / Sales2.74271.63499.06189.72Price / Cash176.7245.1236.6160.67Price / Book4.1810.4112.016.61Net Income-$11.84M-$52.62M$3.32B$276.82M7 Day Performance-2.86%2.10%1.78%2.07%1 Month Performance-8.29%10.86%6.28%2.62%1 Year Performance63.86%13.59%61.13%32.86% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.5868 of 5 stars$13.60-8.2%$30.00+120.6%+54.3%$931.80M$339.84M-104.62280Gap DownSRRKScholar Rock4.4347 of 5 stars$34.28-13.1%$48.60+41.8%+2.5%$3.79B$33.19M-11.78140Gap DownHigh Trading VolumeVKTXViking Therapeutics4.0606 of 5 stars$33.91+1.0%$86.42+154.8%-43.8%$3.77BN/A-22.1620Trending NewsEarnings ReportAnalyst DowngradeAnalyst RevisionGap UpMIRMMirum Pharmaceuticals3.7564 of 5 stars$72.17-0.7%$76.50+6.0%+80.7%$3.65B$336.89M-59.64140LNTHLantheus4.5997 of 5 stars$54.59+2.0%$74.50+36.5%-48.9%$3.64B$1.53B14.52700Trending NewsADMAADMA Biologics3.6304 of 5 stars$14.55+0.1%$27.67+90.1%-2.8%$3.47B$426.45M16.92530News CoveragePositive NewsAnalyst DowngradeACADACADIA Pharmaceuticals3.936 of 5 stars$20.06flat$29.12+45.2%+52.1%$3.38B$957.80M15.08510News CoverageAnalyst ForecastZLABZai Lab2.5822 of 5 stars$31.23+3.3%$56.35+80.4%-3.2%$3.38B$398.99M-15.311,869News CoverageAnalyst ForecastAnalyst RevisionQUREuniQure2.3649 of 5 stars$62.02+0.7%$71.75+15.7%+822.0%$3.38B$27.12M-15.82500Analyst ForecastGap UpCGONCG Oncology2.3208 of 5 stars$42.96-0.7%$58.82+36.9%+17.9%$3.30B$1.14M-24.2761Analyst ForecastAAPGAscentage Pharma Group InternationalN/A$36.45+4.3%N/AN/A$3.26B$390.60M0.00600 Related Companies and Tools Related Companies SRRK Competitors VKTX Competitors MIRM Competitors LNTH Competitors ADMA Competitors ACAD Competitors ZLAB Competitors QURE Competitors CGON Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their car...Crypto 101 Media | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAR Stock Alerts